Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
28 Apr 2026, 16:14:01 UTC
Prior SEC filing
18 Mar 2026
Next SEC filing
14 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Isela Cervantes Rodriguez, as Attorney-in-Fact, for William D. Donovan

Key filing fact

William Dean Donovan filed Form 4 for Controladora Vuela Compania de Aviacion, S.A.B. de C.V. (VLRS) on 28 Apr 2026.

Key facts

  • This page summarizes William Dean Donovan's Form 4 filing for Controladora Vuela Compania de Aviacion, S.A.B. de C.V. (VLRS).
  • 5 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 28 Apr 2026, 16:14.

Change

  • Previous filing in this sequence was filed on 18 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001979736 Primary reporting owner

Donovan William Dean

Relationship
Director
Address
AV. ANTONIO DOVALI JAIME 70, TOWER B, 13, FLOOR, COLONIA ZEDEC SANTA FE, MEXICO CITY, MEXICO
Signature
/s/ Isela Cervantes Rodriguez, as Attorney-in-Fact, for William D. Donovan
Signature date
28 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VLRS transaction

Series A shares of common stock

Options Exercise

Transaction value
Shares
+232,400
Change %
+8.1%
Price
Shares after
3,096,050
Date
28 Apr 2026
Ownership
Direct
Footnotes
F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VLRS transaction Derivative

Restricted Securities Units (Annual Fee)

Award

Transaction value
Shares
+59,260
Change %
Price
$0.000000*
Shares after
59,260
Date
24 Apr 2026
Ownership
Direct
Underlying class
Series A shares of common stock
Underlying amount
59,260
Exercise price
Footnotes
F3, F4
VLRS transaction Derivative

Restricted Securities Units (BoDIP)

Award

Transaction value
Shares
+64,200
Change %
Price
$0.000000*
Shares after
64,200
Date
24 Apr 2026
Ownership
Direct
Underlying class
Series A shares of common stock
Underlying amount
64,200
Exercise price
Footnotes
F3, F4
VLRS transaction Derivative

Restricted Securities Units (Annual Fee)

Options Exercise

Transaction value
Shares
-111,550
Change %
-100%
Price
$0.000000*
Shares after
0
Date
28 Apr 2026
Ownership
Direct
Underlying class
Series A shares of common stock
Underlying amount
111,550
Exercise price
Footnotes
F1, F3
VLRS transaction Derivative

Restricted Securities Units (BoDIP)

Options Exercise

Transaction value
Shares
-120,850
Change %
-100%
Price
$0.000000*
Shares after
0
Date
28 Apr 2026
Ownership
Direct
Underlying class
Series A shares of common stock
Underlying amount
106,461
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Restricted Securities Units ("RSUs") were granted on April 28, 2025 and vest on April 28, 2026. The RSUs have no expiration date.

Footnote F2

Shares owned through American Depositary Shares ("ADSs"). Each ADS representing ten (10) Certificados de Participacion Ordinarios (CPOs). Each CPO representing the economic interest in one (1) share of Series A shares of common stock.

Footnote F3

Each RSU represents a contingent right to receive on Series A share of common stock.

Footnote F4

The RSUs were granted on April 24, 2026 and will vest on April 24, 2027. The RSUs have no expiration date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .